



ASX ANNOUNCEMENT

Update on Economic Evaluation of FebriDx

MELBOURNE, Australia (October 8, 2021) - Lumos Diagnostics Holdings Limited ("**Lumos**" ASX code: "**LDX**") refers to its ASX announcement of 6 October 2021 titled "*Economic Evaluation of FebriDx*" ("**ASX Announcement**").

In the ASX Announcement, Lumos referred to the publication of an article in a peer-reviewed journal (**Journal Article**) on the potential savings for the US Healthcare System that may be achieved from the use of Lumos' FebriDx test at outpatient healthcare settings in the US. Lumos commissioned Avalon Health Economics to undertake the study under a commercial contract but was not involved in the modelling nor aware of the conclusions of the study until the publication was released this week.

The ASX Announcement is not and was not intended to constitute a financial forecast of the potential market for the use of Lumos' FebriDx test. Investors should note generally that possible healthcare "savings" cannot be taken as the size of a potential market. Lumos has not provided any guidance as to possible market size for its Lumos' FebriDx test, the possible pricing of its FebriDx test nor possible market take up or penetration of that potential market. Investors should also note that the Lumos' FebriDx test has not been approved by regulatory authorities, there is considerable risk in seeking regulatory approvals and no guarantee that Lumos will obtain regulatory approval for the Lumos' FebriDx test.

However despite the above, after consultation with the ASX and to clearly provide that the ASX Announcement could not in any way be interpreted as a forecast by Lumos of financial information under ASIC Regulatory Guide 170 - Lumos has agreed to retract the ASX Announcement.

In retracting the ASX Announcement, Lumos notes investors should not:

- rely upon the ASX Announcement for the purpose of making any investment decision concerning Lumos shares; or
- place any weight on either the findings of the Journal Article or the subsequent the Lumos ASX Announcement.

This announcement is authorized for release to the market by the Lumos Disclosure Committee.

###

About Lumos Diagnostics

Lumos Diagnostics specializes in rapid, cost-effective, and complete point-of-care (POC) diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for POC tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded POC tests that target infectious and inflammatory diseases.

For more information visit lumosdiagnostics.com or febridx.com.

Media Contacts (U.S. and Global):

Jennifer Christiansen – Lumos Diagnostics
jennifer.christiansen@lumosdiagnostics.com
+1 920 784 3153

Media Contact (Australia):

Haley Chartres – H^CK
haley@hck.digital
+61 423 139 163

Investor Contact:

Matthijs Smith – Lumos Diagnostics
ir@lumosdiagnostics.com
+61 411 137 080
+61 3 9087 1598

Company Registered Office:

Lumos Diagnostics Holdings Ltd
Level 4, 100 Albert Rd
South Melbourne, VIC 3205
+61 3 9087 1598